Biomanufacturing design and management for therapies and vaccines

GE Healthcare offers drug developers an array of biomanufacturing solutions that increase efficiency and optimize productivity. GE’s Enterprise Solutions provide an end-to-end platform for biologics management with innovative, modular solutions for the launch of new molecules, bringing biosimilars to an emerging market, or expanding biomanufacturing capacity to support production needs. Enterprise Solutions provides clients with new options to achieve their biomanufacturing goals.

FlexFactory™ is an integrated, single-use, or hybrid biomanufacturing platform that provides rapid access to current good manufacturing practice (cGMP) manufacturing capacity, while providing flexibility.

Fast Trak biomanufacturing services

GE provides a wide range of Fast Trak™ support services for drug development applications, including increasing existing capacity, launching a new molecule, and bringing biosimilars to market. The company helps manufacturers stay competitive and maintain high speed-to-market.

Performed with open collaboration and transparency, the company offers services to support cell culture medium development, upstream and downstream process development, clinical manufacturing, analytical development, quality control, and process transfer.

GE’s Fast Trak portfolio supports quick development from molecule to market, ensuring market approval is reached in as short a time and as cost-effectively as possible. The company also accelerates outcomes, mitigates risks and conducts its processes with full transparency to meet its clients’ needs.

Make an enquiry

The biopharmaceutical industry has a reputation for being averse to change. This is likely because traditional approaches to drug development have withstood the test of time, delivering safe and effective drugs for decades.

The Swedish Government and GE Healthcare are opening Testa Center, an innovation centre in Uppsala, Sweden, to boost the commercialisation of new technologies and support manufacturing capabilities in the life sciences sector.

United BioPharma (UBP) has selected GE Healthcare’s FlexFactory manufacturing platform for its new facility focusing on late-stage clinical and commercial production capacity of therapeutic monoclonal antibodies in Hsinchu Industrial Park, Taiwan.

GE has completed a strategic minority investment in Irish-owned Zenith Technologies, a leading technology company delivering manufacturing software systems and solutions for the life sciences industry.

GE Healthcare has announced that Dr. Reddy’s Laboratories will be installing India’s first-ever FlexFactory, a single-use manufacturing platform to expand the biologics production capacity at its facility in Hyderabad, India.